Glenmark Pharmaceuticals Reports Q2 Results

Revenue from operations: Rs 42,473.28 million. Profit after tax: Rs 2,637.83 million.

Reader Takeaway: Revenue remains stable, though a significant one-time US legal settlement charge weighed on quarterly bottom-line performance.

What just happened

Glenmark Pharmaceuticals has released its financial results for the second quarter ending September 30, 2026. The company reported consolidated revenue from operations at Rs 42,473.28 million. Profit before tax stood at Rs 3,382.88 million, while net profit attributable to owners was Rs 2,637.83 million. These results reflect an underlying operating profit before exceptional items of Rs 6,221.63 million.

Why this matters

The headline profit figure was significantly impacted by an exceptional expense of Rs 2,838.75 million. This charge arises from a settlement agreement with Humana, Inc. to resolve antitrust and consumer protection litigation in the United States. While the legal expense has affected reported earnings, the company stated that the settlement does not imply any admission of liability or illegal conduct.

Risks to watch

Investors should consider the recurring risk of legal expenses in international markets. While the current settlement aims to resolve specific claims in the Eastern District of Pennsylvania, any future escalation in other legal proceedings could potentially impact cash flows. The non-recurring nature of this specific charge is critical for evaluating the long-term operational health of the firm.

What to track next

Shareholders should monitor upcoming quarters to assess the stability of core margins now that this significant settlement has been accounted for. The board and audit committee approved these results on November 5, 2026, confirming that pharmaceutical operations remain the company's sole reportable segment.